Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Association of CACNG6 polymorphisms with aspirin-intolerance asthmatics in a Korean population

  • Jin Sol Lee1,
  • Jeong-Hyun Kim1,
  • Joon Seol Bae1,
  • Jason Yongha Kim1,
  • Tae Joon Park1,
  • Charisse Flerida Pasaje1,
  • Byung-Lae Park2,
  • Hyun Sub Cheong2,
  • Soo-Taek Uh3,
  • Jong-Sook Park4,
  • An-Soo Jang4,
  • Mi-Kyeong Kim5,
  • Inseon S Choi6,
  • Choon-Sik Park3Email author and
  • Hyoung Doo Shin1, 2Email author
BMC Medical Genetics201011:138

https://doi.org/10.1186/1471-2350-11-138

Received: 22 June 2010

Accepted: 23 September 2010

Published: 23 September 2010

Abstract

Background

Aspirin-intolerant asthma (AIA) occurs in the lower and upper airways through excessive production of leukotrienes upon administration of non-steroidal anti-inflammatory drugs (NSAIDs). One of the three symptoms of AIA is nasal polyposis, a chronic inflammatory disease that is related to the function of calcium ion in recruitment of immune cells during airway inflammation. It has been implicated that bronchodilation in the airway is related to Ca(2+) regulation. The calcium channel, voltage-dependent, gamma subunit 6 (CACNG6) gene encodes a protein that stabilizes the calcium channel.

Methods

To study the associations between AIA and polymorphisms in CACNG6 gene, eight variants were genotyped in 102 AIA cases and 429 aspirin-tolerant asthma (ATA) controls. Logistic analyses were used to evaluate the associations of CACNG6 polymorphisms with AIA.

Results

Statistical analyses revealed that a single nucleotide polymorphism (SNP; rs192808C > T; P = 0.0004, P corr = 0.0029, OR = 2.88 in co-dominant model; P = 0.0005, P corr = 0.0036, OR = 2.99 in dominant model) in intron and a haplotype unique to this variant (CACNG6_BL1_ht6; P = 0.003, P corr = 0.02, OR = 2.57 in co-dominant model, P = 0.001, P corr = 0.0087, OR = 2.81 in dominant model) were significantly associated with the risk of AIA.

Conclusions

Our results suggest that the CACNG6 variants might be associated with the risk of AIA in a Korean population.

Background

Aspirin-intolerant asthma (AIA), which was first described in 1922, is a unique clinical syndrome associated with acute bronchconstriction upon administration of aspirin and other non-steroidal anti-inflammatory drugs [1]. Although considered as one of the most widely used medication, aspirin intake also incurs various side effects including manifested gastrointestinal ulcer, stomach bleeding and tinnitus especially in higher doses. Although the side effects caused by aspirin are not common, these effects have been reported in about 10% of adult asthmatics.

The triad of AIA symptoms includes aspirin sensitivity, bronchial asthma and chronic rhinosinusitis with nasal polyposis [24]. Nasal polyposis is a chronic inflammatory disease of the upper respiratory tract that affects around two thirds of patients with AIA. The polyps are filled with mast cells and eosinophils due to high levels of the proinflammatory cysteinyl leukotrienes (cysLTs) [5]. After mast cells are activated, it releases a variety of paracrine signals that target tissues such as bronchi and vasculature to recruit other immune cells at the inflammatory site. Among the remarkable signaling molecules released by mast cells, the cysLTs that includes leukotriene C(4) (LTC4), LTD4, and LTE4 are well known [6, 7]. The LTC4 is secreted from mast cells following Ca(2+) influx through store-operated calcium release-activated calcium (CRAC) channels [710]. It has also been reported that proteinase activated receptor-2 (PAR2), as a novel emerging pharmacological target in airway diseases, is expressed in the airway epithelium and its activation may be involved in the protective role of preserving bronchial functionality [11, 12]. In line with the fact that the airway smooth muscle cell contraction is regulated by changes in intracellular Ca(2+) concentration, a previous molecular report has revealed a relationship between this Ca(2+) regulation and bronchodilation in the airway [13]. More recently, novel actions of NSAIDs on vascular ion channels including L-type calcium channel has also been suggested [14].

The L-type calcium channels are composed of five subunits. The CACNG6 gene encodes one of these subunits, specifically a gamma subunit protein which was first identified in muscle cells [15]. Recent studies have revealed negative relations of CACNG6 gene expression to chronic obstructive pulmonary disease, responses of the human airway epithelium following injury and % parenchyma in lung tissues [16, 17]. The CACNG6 is an integral membrane protein that stabilizes the calcium channel during its inactive state [18]. Since the role of azelastine in asthma treatment is achieved by blocking the L-type calcium channel thus, preventing Ca(2+) current [19], the CACNG6 may, therefore, be of interest in the study of asthma treatment. Moreover, abnormal Ca(2+) influx may induce leukotriene overproduction from mast cells, leading to recruitment of other immune cells, such as eosinophils, resulting in vasospasm by eosinophilic infiltration of the coronary artery wall and cardiac contractility [8, 20]. Although many signaling pathways have been known to underlie the reversible contraction of airway smooth muscle, ionic mechanisms related to Ca(2+) and the calcium channels in the airways are still poorly understood [21]. In this connection, we explored whether CACNG6 single nucleotide polymorphisms (SNPs) are associated with AIA.

Methods

Study Subjects

Subjects in this study were recruited from the Asthma Genome Research Center comprising hospitals of Soonchunhyang, Chunnam, Chungbuk, Seoul National and Chung-Ang Universities in Korea. All subjects provided written informed consents and the study protocols were approved by the Institutional Review Board of each hospital. Diagnosis of AIA was performed according to a modified method as previously described [22]. We also performed aspirin challenge in subjects with a history of aspirin hypersensitivity, presence of urticaria, nasal polyps and sinusitis. The AIA case group included patients with 20% or greater decreases in FEV1 or 15% to 19% decreases in FEV1 with naso-ocular or cutaneous reactions, whereas subjects showing a rate of FEV1 decline less than 15% without extrabronchial, nasal or skin symptoms were included in ATA group.

SNP selection and genotyping

We selected 8 common polymorphic SNPs from the International HapMap Project phase 1&2 http://hapmap.ncbi.nlm.nih.gov/ and National Center for Biotechnology Information (build 36) based on the minor allele frequency (> 0.05) and LD status. Among three SNPs (rs3810244, rs158194, rs4806481) in LD (|D'| > 0.7), the most common SNP (rs4806481) was selected for genotyping. For examination of AIA risk association, we genotyped 8 common SNPs in the CACNG6 gene. Genotyping was carried out with 20 ng of genomic DNA by TaqMan assay in the ABI prism 7900HT sequence detection system software version 2.3 (Applied Biosystems, CA, USA) in 102 AIA cases and 429 ATA controls with the assessment of data quality by duplicate DNAs (n = 10). A total of 8 polymorphisms on CACNG6 were successfully genotyped.

Statistics

We calculated linkage disequilibrium to all pairs of biallelic loci using Lewontin's D' (|D'|) [23] and r 2 . PHASE algorithm (ver. 2.0) developed by Stephens et al. was used for inferring haplotypes [24]. Associations of genotypes and haplotypes in the CACNG6 gene with AIA were calculated using logistic analyses adjusted for age, gender, smoking status, atopy and body mass index as covariates. We also performed linear regression analysis to determine the differences in the rates of decline in FEV1 following aspirin challenge among the genotypes and haplotypes. The data were adjusted, managed and analyzed using SAS version 9.1 (SAS Inc., Cary, NC). The effective number of independent marker loci (7.28) was calculated for multiple testing corrections using SNPSpD software http://genepi.qimr.edu.au/general/daleN/SNPSpD/, which is based on the spectral decomposition (SpD) of matrices of pair-wise LD between SNPs.

Results

In this study, the clinical characteristics of the study subjects showed that the fall rate by aspirin provocation in AIA patients was significantly higher than that of ATA controls (33.59 ± 13.42% vs. 3.54 ± 4.85%, respectively; P < 0.0001). This was in contrast to the current smoker ratio and mean age which was higher in ATA controls than those of AIA patients (21.36% vs. 30.07% for smoking status and 42.76 year vs. 47.30 year for mean age, respectively). Body mass index (BMI) and PC20 methacholine test also showed significant signals (P < 0.01). In addition, AIA patients were more sensitive to methacholine than ATA patients (4.26 mg/ml vs. 6.91 mg/ml). Analyses on other factors in subject's clinical characteristics showed no significant differences between AIA and ATA groups. The clinical characteristics of the study subjects are summarized in Table 1.
Table 1

Clinical profiles of aspirin intolerance asthma and control subjects

Clinical profile

AIA

ATA

Number of subjects (n)

102

429

Age [year, mean (range)]

42.76 (18.66-72.73)*

47.30 (15.40-77.88)

Sex (n, male/female)

37/65

147/282

Smoker (current smoker/exsmoker) (%)

21.36 (13.59/7.77)*

30.07 (12.35/17.72)

Height [cm, mean (range)]

161.70 ± 9.91

160.42 ± 8.39

Weight (kg)

61.64 ± 10.39

63.40 ± 10.97

Body mass index (kg/m2)

23.56 ± 3.37*

24.58 ± 3.39

% decline of FEV1 by aspirin provocation

33.59 ± 13.42**

3.54 ± 4.85

Blood eosinophil (%)

6.65 ± 5.78

6.03 ± 5.92

FEV1 (% predicted)

85.10 ± 16.41*

91.66 ± 16.87

PC20 methacholine (mg/ml)

4.26 ± 7.62*

6.91 ± 8.90

Total IgE (IU/ml)

415.74 ± 714.70

361.00 ± 607.56

Positive rate of skin test (%)

48.04

57.81

Age indicates a first medical examination. AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma.

*P < 0.05; **P < 0.0001 compared to ATA control.

To investigate the association of CACNG6 polymorphisms with AIA, 8 SNPs (rs251850, rs4806481, rs158196, rs158199, rs192808, rs450227, rs2291068, rs459247) in the CACNG6 gene were genotyped in a total of 531 study subjects including 102 AIA patients as a case group and 429 ATA patients as controls. The genotype distributions of all loci were in Hardy-Weinberg equilibrium (Table 2, P > 0.05). Genetic map and location of CACNG6 polymorphisms are shown in Fig. 1A. Logistic analysis was used to analyze whether the genetic polymorphisms were associated with AIA. Interestingly, analysis revealed that a SNP in intron (rs192808C > T; OR = 2.88, 95% CI = 1.60-5.17, P = 0.0004, P corr = 0.0029 in co-dominant model), which was more frequent in AIA patients than in ATA controls (0.103 in AIA patients and 0.045 in ATA patients) (Table 2), was significantly associated with the risk of AIA even after multiple testing corrections. In additional analysis using effective models, this allelic variant also showed a susceptibility to AIA in dominant model (OR = 2.99, 95% CI = 1.62-5.54, P = 0.0005, P corr = 0.0036).
Table 2

SNPs information and logistic analysis for CACNG6

SNP/Haplotype

Allele change

Position

Frequency

Hetero-zygosity

Frequencya

HWE

Co-dominant

Dominant

Recessive

     

AIA

ATA

AIA

ATA

OR(95%CI)

P

P corr

OR(95%CI)

P

P corr

OR(95%CI)

P

P corr

rs251850

T > C

Promoter

0.176

0.29

0.176

0.177

0.904

0.139

0.97 (0.64-1.49)

0.9

-

0.93(0.58-1.49)

0.75

-

1.49(0.38-5.94)

0.57

-

rs4806481

C > T

Intron

0.482

0.499

0.451

0.488

0.766

0.461

0.89(0.64-1.22)

0.45

-

0.84(0.52-1.37)

0.49

-

0.86(0.50-1.49)

0.6

-

rs158196

A > G

Intron

0.35

0.455

0.363

0.348

0.499

0.537

0.99(0.72-1.37)

0.96

-

0.95(0.60-1.49)

0.82

-

1.08(0.57-2.04)

0.81

-

rs158199

G > A

Intron

0.24

0.364

0.255

0.233

0.474

0.124

1.03(0.73-1.46)

0.87

-

1.03(0.66-1.62)

0.88

-

1.05(0.45-2.41)

0.92

-

rs192808

C > T

Intron

0.058

0.11

0.103

0.045

0.931

0.899

2.88(1.60-5.17)

0.0004

0.0029

2.99(1.62-5.54)

0.0005

0.0036

6.11(0.28-131.25)

0.25

-

rs450227

C > T

Intron

0.146

0.25

0.167

0.145

0.552

0.444

1.1(0.71-1.70)

0.67

-

1.13(0.69-1.83)

0.63

-

0.98(0.19-5.01)

0.98

-

rs2291068

T > C

Exon

0.199

0.319

0.225

0.192

0.645

0.562

1.08(0.73-1.58)

0.71

-

1.04(0.66-1.64)

0.88

-

1.43(0.52-3.96)

0.49

-

rs459247

G > A

Exon

0.5

0.5

0.426

0.515

0.558

0.542

0.75(0.55-1.03)

0.07

0.54

0.66(0.41-1.07)

0.09

0.68

0.71(0.41-1.22)

0.21

-

CACNG6_BL1_ht1

  

0.339

0.448

0.324

0.338

0.884

0.665

0.97(0.70-1.36)

0.87

-

0.94(0.60-1.47)

0.78

-

1.03(0.51-2.11)

0.93

-

CACNG6_BL1_ht2

  

0.207

0.328

0.211

0.202

0.142

0.095

0.97(0.67-1.41)

0.88

-

0.93(0.58-1.47)

0.74

-

1.14(0.46-2.80)

0.78

-

CACNG6_BL1_ht3

  

0.153

0.259

0.152

0.154

0.62

0.242

0.94(0.60-1.46)

0.77

-

0.87(0.53-1.43)

0.58

-

1.72(0.42-7.09)

0.45

-

CACNG6_BL1_ht4

  

0.097

0.175

0.083

0.104

0.705

0.472

0.8(0.46-1.38)

0.41

-

0.78(0.43-1.41)

0.41

-

0.77(0.09-6.70)

0.82

-

CACNG6_BL1_ht5

  

0.082

0.151

0.054

0.093

0.565

0.677

0.57(0.29-1.12)

0.1

0.76

0.58(0.29-1.15)

0.12

0.85

.

0.99

-

CACNG6_BL1_ht6

  

0.057

0.107

0.093

0.045

0.3

0.899

2.57(1.39-4.73)

0.003

0.02

2.81(1.51-5.24)

0.001

0.0087

.

0.99

-

CACNG6_BL2_ht1

  

0.495

0.5

0.422

0.509

0.447

0.6

0.75(0.55-1.03)

0.07

0.52

0.65(0.40-1.04)

0.07

0.52

0.73(0.42-1.26)

0.26

-

CACNG6_BL2_ht2

  

0.29

0.412

0.338

0.283

0.238

0.538

1.31(0.94-1.83)

0.11

0.77

1.66(1.06-2.60)

0.03

0.2

0.93(0.43-2.04)

0.86

-

CACNG6_BL2_ht3

  

0.13

0.226

0.152

0.129

0.785

0.173

1.1(0.69-1.74)

0.68

-

1.07(0.65-1.77)

0.78

-

1.76(0.30-10.15)

0.53

-

CACNG6_BL2_ht4

  

0.068

0.127

0.069

0.063

0.457

0.567

0.93(0.49-1.77)

0.83

-

0.96(0.50-1.84)

0.89

-

.

0.99

-

aThe frequency of SNP indicates the minor allele frequency.

HWE, Hardy-Weinberg equilibrium; P corr , corrected P-value using multiple testing corrections.

AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma; AA, amino acid; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval

Figure 1

Gene maps and haplotypes of the CACNG6 gene. Schematic physical map, haplotypes and LD plot of CACNG6. (A) Polymorphisms identified in CACNG6. Coding exons are marked by shaded blocks and 3'-untranslated region (UTR) by white blocks. The LD coefficients (r 2) are based on the genotypes of Korean samples. (B) Haplotypes of CACNG6 in the Korean population. Only those with frequencies over 0.05 are shown in Table 2 and 3. (C) LD coefficients (|D'|) among the selected SNPs based on the genotypes of whole study subjects in this study. (D) LD coefficients (|D'|) in AIA and ATA.

Based on the 8 polymorphisms, haplotypes were calculated using PHASE software resulting in two haplotype blocks (Fig. 1B and 1C). Although a different pattern in Block 1 between AIA and ATA was observed (Fig. 1D), the haplotypes which were composed of five SNPs were used for the association analysis because they were estimated as common haplotypes derived from a large number of subjects in the Korean population. Among the haplotypes, CACNG6_BL1_ht6, the only one containing the rare T variant of rs192808, also showed significant association with risk of AIA (P = 0.003, P corr = 0.02 in co-dominant model; P = 0.001, P corr = 0.0087 in dominant model), showing a similar pattern with the association of rs192808 SNP (Table 2). In the case of CACNG6_BL1_ht6 haplotype, the frequency of AIA patients was higher at about two-fold than that of ATA controls (0.093 and 0.045, respectively).

Next, we performed regression analysis for the association between decline of FEV1 by aspirin provocation and CACNG6 polymorphisms. As summarized in Table 3, among all the variants and haplotypes, SNP rs192808 (P = 0.006 in co-dominant model and P = 0.01 in dominant model) and haplotype CACNG6_BL1_ht6 (P = 0.03 in co-dominant model and P = 0.02 in dominant model) showed the most significant signal. In addition, in the second LD block, haplotype CACNG6_BL2_ht2 showed an association with the decline of FEV1 by aspirin provocation in the dominant model (P = 0.03). However, in further regression analysis using only AIA cases, no significant associations were detected (Additional file 1, Table S1), indicating that rs192808 and haplotypes of CACNG6 could not directly affect the aspirin-induced decline of FEV1 in AIA patients.
Table 3

Regression analysis between SNPs and haplotypes of CACNG6 in all subjects

SNP or Haplotype

Position

C/C

C/R

R/R

Pa

Pb

Pc

rs251850

Promoter

397 (9.41 ± 13.26)

180 (8.48 ± 12.24)

15 (13.60 ± 21.54)

0.91

0.57

0.19

rs4806481

Intron

153 (10.09 ± 13.84)

308 (9.34 ± 13.47)

129 (8.07 ± 11.90)

0.25

0.38

0.32

rs158196

Intron

251 (9.19 ± 13.69)

265 (8.81 ± 12.70)

76 (10.85 ± 13.47)

0.75

0.79

0.29

rs158199

Intron

349 (8.92 ± 12.97)

204 (9.63 ± 13.63)

39 (9.97 ± 13.55)

0.75

0.78

0.81

rs192808

Intron

529 (8.81 ± 12.99)

60 (12.35 ± 13.94)

3 (21.67 ± 28.36)

0.006

0.01

0.06

CACNG6_BL1_ht1

 

259 (9.55 ± 13.60)

271 (9.11 ± 12.76)

62 (8.45 ± 13.77)

0.64

0.68

0.73

CACNG6_BL1_ht2

 

382 (9.19 ± 13.48)

178 (9.05 ± 12.56)

32 (10.72 ± 13.99)

0.98

0.82

0.59

CACNG6_BL1_ht3

 

421 (9.34 ± 13.30)

159 (8.41 ± 11.88)

12 (16.39 ± 23.38)

0.92

0.64

0.07

CACNG6_BL1_ht4

 

481 (9.40 ± 13.60)

104 (8.67 ± 11.80)

7 (6.14 ± 2.97)

0.5

0.56

0.57

CACNG6_BL1_ht5

 

493 (9.52 ± 13.23)

96 (7.91 ± 13.32)

3 (4.67 ± 2.31)

0.32

0.33

0.66

CACNG6_BL1_ht6

 

530 (8.83 ± 12.99)

60 (12.90 ± 14.91)

2 (5.50 ± 6.36)

0.03

0.02

0.69

rs450227

Intron

426 (9.18 ± 13.11)

157 (9.38 ± 13.56)

9 (9.33 ± 13.76)

0.89

0.91

0.87

rs2291068

Exon

378 (9.17 ± 13.17)

194 (9.40 ± 13.14)

20 (8.72 ± 15.41)

0.69

0.79

0.61

rs459247

Exon

150 (11.12 ± 15.52)

290 (8.74 ± 11.28)

152 (8.32 ± 14.07)

0.12

0.06

0.48

CACNG6_BL2_ht1

 

153 (11.09 ± 15.38)

290 (8.70 ± 11.28)

149 (8.37 ± 14.19)

0.12

0.06

0.50

CACNG6_BL2_ht2

 

301 (8.17 ± 12.70)

240 (10.55 ± 13.87)

51 (9.34 ± 12.78)

0.09

0.03

0.97

CACNG6_BL2_ht3

 

442 (9.37 ± 13.28)

145 (8.72 ± 12.92)

5 (11.80 ± 18.75)

0.51

0.44

0.75

CACNG6_BL2_ht4

 

515 (9.12 ± 13.08)

76 (9.99 ± 14.29)

1 (8.00)

0.86

0.83

0.78

C/C, common allele/common allele; C/R, common allele/rare allele; R/R, rare allele/rare allele;

Pa, P-values of co-dominant model; Pb, dominant model; Pc, recessive model.

Discussion

Although over-production of pro-inflammatory cysLTs such as LTC4, LTD4 and LTE4 has been considered as a main cause of aspirin hypersensitivity in asthma [25], recent studies have suggested that other genes may be related to AIA [21, 26, 27]. On the other hand, previous studies have reported that concentration of calcium ion is related with leukotriene secretion [28] and that CACNG6 gene is negatively expressed in chronic obstructive pulmonary disease and human airway epithelium following injury [16, 17]. Considering these facts, we hypothesized that the modulation of calcium concentration could play an important role in abnormal signaling pathways in the airways and that the CACNG6 gene, as a subunit of L-type calcium channels, and its polymorphisms might be associated with risk of AIA.

Although the minor T allele of rs192808 and its unique haplotype (CACNG6_BL1_ht6) showed significant association signals with decline of FEV1 (Table 3), allelic dose effect revealed no consistent results of decline of FEV1 between rs192808 and CACNG6_BL1_ht6 due to the small number of rare alleles (R/R), therefore further replication studies are needed for a correct association. Among polymorphisms in the CACNG6 gene, the rs192808 polymorphism in intronic region showed a highly significant signal. It has also been found that CACNG6 has three transcripts. Thus, to predict role of rs192808, we performed GeneSplicer http://www.cbcb.umd.edu/software/GeneSplicer and EMBL-EBI splice site prediction tool http://www.ebi.ac.uk/asd-srv/wb.cgi?method=2 to know whether rs192808 could be located in splicing association site [29]. However, results showed that the rs192808 was not located in any splicing-related site such as donor site (5' boundary), acceptor site (3' boundary) and branch point. In addition, the functionality of other SNPs that were in LD with rs192808 was analyzed. However, results from the Signal Scan program http://www-bimas.cit.nih.gov/molbio/signal/ revealed that CACNG6 rs251850 in promoter region was not a transcriptional element, and three intronic SNPs (rs4806481, rs158196, rs158199) were not predicted as splicing-related sites.

A previous study has reported that some SNPs located deep in intronic region can create new transcription factor binding site [30]. Thus, we further performed TFSEARCH http://www.cbrc.jp/research/db/TFSEARCH.html using bioinformatical software to predict whether rs192808 can create transcription binding site. However, results showed that the location of rs192808 is not in the transcription factor binding site. Even if these results suggest that rs192808 may not affect the function of CACNG6, previous studies reported that sometimes allelic variants in intron can lead to the onset of human diseases due to alterations in the expression level of mRNA caused by creating potential aberrant splice sites [31, 32]. Moreover, additional transcriptional isoforms of the CACNG6 gene have been discovered from the Mammalian Gene Collection (MGC) Program [33] as shown in the Ensembl Genome Browser http://www.ensembl.org/index.html (Additional files 3, Figure S1). Therefore, findings from our study on the significant association between rs192808 and AIA needs to be replicated and/or further analyzed in order to understand its detailed function in the mechanism of AIA.

Since there is a possibility that CACNG6 SNPs are in LD with functional SNP(s) that is/are located in a different gene in the nearby region, we further analyzed the LD near CACNG6 in Asian populations (Japanese and Chinese) from the International HapMap Project. However, the CACNG6 gene showed no LD with other nearby genes (Additional files 4, Figure S2). On the other hand, although minor allele frequencies of 8 SNPs validated in Korean asthmatics were similar to those of Asian populations (Chinese and Japanese), significant differences were detected from other populations especially in rs158196, rs1581199, rs192808, rs450227, rs2291068, and rs459247 (Additional files 2, Table S2). When comparing LDs on 8 SNPs of CACNG6 among Korean asthmatic patients and other populations (Additional file 5, Figure S3), albeit non-asthmatic Korean population has not determined, it can be assumed that a different LD status of the asthmatics may affect AIA and/or asthma-related phenotypes at least in a Korean population. Moreover, although replications and functional studies are needed, rs192808 and CACNG6_BL1_ht6 could be genetic markers of AIA susceptibility.

Conclusions

Although replication for the associations is required in an independent study cohort to validate our findings, this study showed that the genetic polymorphisms of CACNG6 might be associated with risk of AIA at least in a Korean population, providing a new link between voltage-dependent calcium channel and aspirin hypersensitivity in asthmatics. Further functional and replication studies elsewhere are needed to identify the roles of the polymorphisms of the gene.

List of Abbreviations

AIA: 

aspirin-intolerant asthma

ATA: 

aspirin-tolerant asthma

CACNG6: 

calcium channel: voltage-dependent: gamma subunit 6

SNP: 

single nucleotide polymorphism

MAF: 

minor allele frequency

LD: 

linkage disequilibrium

OR: 

odds ratio

CI: 

confidence interval

Declarations

Acknowledgements

This work was supported by a grant from the Korea Health 21 R&D Project (A010249); a grant number M1-0302-00-0073 from Korea Science and Engineering Foundation (KOSEF) funded by the Korea government (MEST) (No. 2009-0080157); an Intramural Research Grant of the Korea National Institute of Health (grant number 4800-4845-300-260-00); and a Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093822). The DNA samples were generously provided by the Soonchunhyang University, Bucheon Hospital Biobank, a member of the National Biobank of Korea, supported by the Ministry of Health, Welfare and Family Affairs, Republic of Korea.

Authors’ Affiliations

(1)
Department of Life Science, Sogang University
(2)
Department of Genetic Epidemiology, SNP Genetics, Inc.
(3)
Division of Allergy and Respiratory Medicine, Soonchunhyang University Seoul Hospital
(4)
Genome Research Center for Allergy and Respiratory Disease, Soonchunhyang University Bucheon Hospital
(5)
Division of Internal Medicine, Chungbuk National University, College of Medicine
(6)
Department of Allergy, Chonnam National University Medical School and Research Institute of Medical Sciences

References

  1. Widal F, Abrami P, Lermoyez J: Anaphylaxie et idiosyncrasie. 1992 [Anaphylaxis and idiosyncrasy. 1992]. Allergy Proc. 1993, 14 (5): 373-376. 10.2500/108854193778774065. discussion 371-372View ArticlePubMedGoogle Scholar
  2. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003, 111 (5): 913-921. 10.1067/mai.2003.1487. quiz 922View ArticlePubMedGoogle Scholar
  3. Samter M, Beers RF: Concerning the nature of intolerance to aspirin. J Allergy. 1967, 40 (5): 281-293. 10.1016/0021-8707(67)90076-7.View ArticlePubMedGoogle Scholar
  4. Stevenson DD, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001, 87 (3): 177-180. 10.1016/S1081-1206(10)62221-1.View ArticlePubMedGoogle Scholar
  5. Pawankar R: Nasal polyposis: an update: editorial review. Curr Opin Allergy Clin Immunol. 2003, 3 (1): 1-6. 10.1097/00130832-200302000-00001.View ArticlePubMedGoogle Scholar
  6. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001, 294 (5548): 1871-1875. 10.1126/science.294.5548.1871.View ArticlePubMedGoogle Scholar
  7. Chang WC, Nelson C, Parekh AB: Ca2+ influx through CRAC channels activates cytosolic phospholipase A2, leukotriene C4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells. Faseb J. 2006, 20 (13): 2381-2383. 10.1096/fj.06-6016fje.View ArticlePubMedGoogle Scholar
  8. Di Capite J, Shirley A, Nelson C, Bates G, Parekh AB: Intercellular Ca2+ wave propagation involving positive feedback between CRAC channels and cysteinyl leukotrienes. Faseb J. 2009, 23 (3): 894-905. 10.1096/fj.08-118935.View ArticlePubMedGoogle Scholar
  9. Chang WC, Parekh AB: Close functional coupling between Ca2+ release-activated Ca2+ channels, arachidonic acid release, and leukotriene C4 secretion. J Biol Chem. 2004, 279 (29): 29994-29999. 10.1074/jbc.M403969200.View ArticlePubMedGoogle Scholar
  10. Chang WC, Di Capite J, Nelson C, Parekh AB: All-or-none activation of CRAC channels by agonist elicits graded responses in populations of mast cells. J Immunol. 2007, 179 (8): 5255-5263.View ArticlePubMedGoogle Scholar
  11. Cocks TM, Moffatt JD: Protease-activated receptor-2 (PAR2) in the airways. Pulm Pharmacol Ther. 2001, 14 (3): 183-191. 10.1006/pupt.2001.0285.View ArticlePubMedGoogle Scholar
  12. Morello S, Vellecco V, Roviezzo F, Maffia P, Cuzzocrea S, Cirino G, Cicala C: A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats. Biochem Pharmacol. 2005, 71 (1-2): 223-230. 10.1016/j.bcp.2005.10.016.View ArticlePubMedGoogle Scholar
  13. Sanderson MJ, Delmotte P, Bai Y, Perez-Zogbhi JF: Regulation of airway smooth muscle cell contractility by Ca2+ signaling and sensitivity. Proc Am Thorac Soc. 2008, 5 (1): 23-31. 10.1513/pats.200704-050VS.View ArticlePubMedGoogle Scholar
  14. Brueggemann LI, Mani BK, Mackie AR, Cribbs LL, Byron KL: Novel Actions of Nonsteroidal Anti-Inflammatory Drugs on Vascular Ion Channels: Accounting for Cardiovascular Side Effects and Identifying New Therapeutic Applications. Mol Cell Pharmacol. 2 (1): 15-19.Google Scholar
  15. Glossmann H, Striessnig J, Ferry DR, Goll A, Moosburger K, Schirmer M: Interaction between calcium channel ligands and calcium channels. Circ Res. 1987, 61 (4 Pt 2): I30-36.PubMedGoogle Scholar
  16. Wang IM, Stepaniants S, Boie Y, Mortimer JR, Kennedy B, Elliott M, Hayashi S, Loy L, Coulter S, Cervino S, et al: Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med. 2008, 177 (4): 402-411. 10.1164/rccm.200703-390OC.View ArticlePubMedGoogle Scholar
  17. Heguy A, Harvey BG, Leopold PL, Dolgalev I, Raman T, Crystal RG: Responses of the human airway epithelium transcriptome to in vivo injury. Physiol Genomics. 2007, 29 (2): 139-148.View ArticlePubMedGoogle Scholar
  18. Lin Z, Witschas K, Garcia T, Chen RS, Hansen JP, Sellers ZM, Kuzmenkina E, Herzig S, Best PM: A critical GxxxA motif in the gamma6 calcium channel subunit mediates its inhibitory effect on Cav3.1 calcium current. J Physiol. 2008, 586 (Pt 22): 5349-5366. 10.1113/jphysiol.2008.159111.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Li S, Blaschke M, Heubach JF, Wettwer E, Ravens U: Effects of azelastine on contractility, action potentials and L-type Ca(2+) current in guinea pig cardiac preparations. Eur J Pharmacol. 2001, 418 (1-2): 7-14. 10.1016/S0014-2999(01)00923-2.View ArticlePubMedGoogle Scholar
  20. Wong CW, Luis S, Zeng I, Stewart RA: Eosinophilia and coronary artery vasospasm. Heart Lung Circ. 2008, 17 (6): 488-496. 10.1016/j.hlc.2008.06.003.View ArticlePubMedGoogle Scholar
  21. Akahoshi M, Obara K, Hirota T, Matsuda A, Hasegawa K, Takahashi N, Shimizu M, Nakashima K, Cheng L, Doi S, et al: Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma. Hum Genet. 2005, 117 (1): 16-26. 10.1007/s00439-005-1285-0.View ArticlePubMedGoogle Scholar
  22. Park HS: Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy. 1995, 25 (1): 38-40. 10.1111/j.1365-2222.1995.tb01000.x.View ArticlePubMedGoogle Scholar
  23. Hedrick PW: Gametic disequilibrium measures: proceed with caution. Genetics. 1987, 117 (2): 331-341.PubMedPubMed CentralGoogle Scholar
  24. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001, 68 (4): 978-989. 10.1086/319501.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Tantisira KG, Drazen JM: Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol. 2009, 124 (3): 422-427. 10.1016/j.jaci.2009.06.035.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Kim SH, Ye YM, Lee SK, Choi JH, Holloway JW, Park CS, Park HS: Association of TNF-alpha genetic polymorphism with HLA DPB1*0301. Clin Exp Allergy. 2006, 36 (10): 1247-1253. 10.1111/j.1365-2222.2006.02567.x.View ArticlePubMedGoogle Scholar
  27. Hitomi Y, Ebisawa M, Tomikawa M, Imai T, Komata T, Hirota T, Harada M, Sakashita M, Suzuki Y, Shimojo N, et al: Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol. 2009, 124 (4): 779-785. 10.1016/j.jaci.2009.07.044. e776View ArticlePubMedGoogle Scholar
  28. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B: Leukotrienes are potent constrictors of human bronchi. Nature. 1980, 288 (5790): 484-486. 10.1038/288484a0.View ArticlePubMedGoogle Scholar
  29. Pertea M, Lin X, Salzberg SL: GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res. 2001, 29 (5): 1185-1190. 10.1093/nar/29.5.1185.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Pagani F, Buratti E, Stuani C, Bendix R, Dork T, Baralle FE: A new type of mutation causes a splicing defect in ATM. Nat Genet. 2002, 30 (4): 426-429. 10.1038/ng858.View ArticlePubMedGoogle Scholar
  31. Amsellem S, Briffaut D, Carrie A, Rabes JP, Girardet JP, Fredenrich A, Moulin P, Krempf M, Reznik Y, Vialettes B, et al: Intronic mutations outside of Alu-repeat-rich domains of the LDL receptor gene are a cause of familial hypercholesterolemia. Hum Genet. 2002, 111 (6): 501-510. 10.1007/s00439-002-0813-4.View ArticlePubMedGoogle Scholar
  32. King K, Flinter FA, Nihalani V, Green PM: Unusual deep intronic mutations in the COL4A5 gene cause × linked Alport syndrome. Hum Genet. 2002, 111 (6): 548-554. 10.1007/s00439-002-0830-3.View ArticlePubMedGoogle Scholar
  33. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, et al: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA. 2002, 99 (26): 16899-16903. 10.1073/pnas.242603899.View ArticlePubMedGoogle Scholar
  34. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/11/138/prepub

Copyright

© Lee et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement